Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines

Hiroshima Journal of Medical Sciences

Volumn 49, Issue 1, 2000, Pages 67-72

  Tanabe, Tetsuyuki ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

4 HPR; PAI 1; Prostate cancer; uPA

Indexed keywords

FENRETINIDE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL LYSATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CYCLOHEXIMIDE; FENRETINIDE; GENE EXPRESSION; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; RNA STABILITY; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034009782     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Andreasen, P.A., Georg, B., Lund, L.R., Riccio, A. and Stacey, S.N. 1990. Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol. 68: 1-19.
2. Bartha, K., Declerck, P.J., Moreau, H., Nelles, L. and Collen, D. 1991. Synthesis and Secretion of Plasminogen Activator Inhibitor 1 by Human Endothelial Cells in Vitro. J. Biol. Chem. 266: 792-797.
3. Clifford, J.L., Petkovich, M., Chambon, P. and Lotan, R. 1990. Modulation by Retinoids of mRNA Levels for Nuclear Retinoic Acid Receptors in Murine Melanoma Cells. Mol. Endo. 4: 1546-1555.
4. Costa, A., Formelli, F., Chiesa, F., Decensi, A., De Palo, G. and Veronesi, U. 1994. Prospects of Chemoprevention of Human Cancers with the Synthetic Retinoid Fenretinide. Cancer Res. 54: 2032-2037.
5. Formelli, F. and Cleris, L. 1993. Synthetic Retinoid Fenretinide Is Effective against a Human Ovarian Carcinoma Xenograft and Potentiates Cisplatin Activity. Cancer Res. 53: 5374-5376.
6. Fourney, R.M., Miyakoshi, J., Day, R.S., III and Paterson, M.C. 1988. Northern blotting: efficient RNA staining and transfer. Focus 10: 5-7.
7. Green, S. 1993. Promiscuous liaisons. Nature 361: 590-591.
8. Guss, S.P., Chodak, G.W. and Rukstalis, D.B. 1992. Inhibition of growth and invasion in human prostatic carcinoma cell lines by N-Retinamide. Sur. Forum 43: 740-742.
9. Iizumi, T., Yazaki, T., Kanoh, S., Kondo, I. and Koiso, K. 1987. Establishment of a New Prostatic Carcinoma Cell Line (TSU-PR1). J. Urol. 137: 1304-1306.
10. Kaighn, M.E., Narayan, K.S., Ohnuki, Y., Iechner, J.F. and Jones, L.W. 1979. Establishment and Characterization of a Human Prostatic Carcinoma Cell Line (PC3). Invest. Urol. 17: 16-23.
11. Kim, J.H., Tanabe, T., Chocak, G.W. and Rukstalis, D.B. 1995. In Vitro Anti-invasive Effects of N-(4-hydroxyphenyl)-retinamide on Human Prostatic Adenocarcinoma. Anticancer Res. 15: 1429-1434.
12. Ledinko, N. and Costantino, R.L. 1990. Modulation of p53 Gene Expression and Cytokeratin 18 in Retinoid-Mediated Invasion Suppressed Lung Carcinoma Cells. Anticancer Res. 10: 1335-1340.
13. Liotta, L.A. 1986. Tumor Invasion and Metastases - Role of the Extracellular Matrix: Rhoads Memorial Award Lecture. Cancer Res. 46: 1-7.
14. Moon, R.C., Kelloff, G.J., Detrisac, C.J., Steele, V.E., Thomas, C.F. and Sigman, C.C. 1994. Chemoprevention of OH-BBN-Induced Bladder Cancer in Mice by Oltipraz, Alone and in Combination with 4-HPR and DFMO. Anticancer Res. 14: 5-11.
15. Moon, R.C., Thompson, H.J., Beccl, P.J., Grubbs, C.J., Gander, R.J., Newton, D.L., Smith, J.M., Phillips, S.L., Henderson, W.R., Mullen, L.T., Brown, C.C. and Sporn, M.B. 1979. N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat. Cancer Res. 39: 1339-1346.
16. Nakajima, M., Lotan, D., Baig, M.M., Carralero, R.M., Wood, W.R., Hendrix, M.J.C. and Lotan, R. 1989. Inhibition by Retinoic Acid of Type IV Collagenolysis and Invasion through Reconstituted Basement Membrane by Metastatic Rat Mammary Adenocarcinoma Cells. Cancer Res. 49: 1698-1706.
17. Ossowski, L., Clunie, G., Masucci, M. T. and Blasi, F. 1991. In Vivo Paracrine Interaction between Urokinase and Its Receptor: Effect on Tumor Cell Invasion. J. Cell Biol. 15: 1107-1112.
18. Roberson, K.M., Penland, S.N., Padilla, G.M., Selvan, R.S., Kim, C.S., Fine, R.L. and Robertson, C.N. 1997. Fenretinide: Induction of Apoptosis and Endogenous Transforming Growth Factor β in PC-3 Prostate Cancer Cells. Cell Growth Differ. 8: 101-111.
19. Schmitt, M., Janicke, F., Moniwa, N., Chucholowski, N., Pache, L. and Graeff, H. 1992. Tumor-Associated Urokinase-Type Plasminogen Activator: Biological and Clinical Significance. Biol. Chem. Hoppe-Seyler 373: 611-622.
20. Schneiderman, J., Sawdey, M.S., Keeton, M.R., Bordin, G.M., Bernstein, E.F., Dilley, R.B. and Loskutoff, D.J. 1992. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. 89: 6998-7002.
21. Stearns, M.E., Wang, M. and Fudge, K. 1993. Liarozole and 13-cis-Retinoic Acid Anti-Prostatic Tumor Activity. Cancer Res. 53: 3073-3077.
22. van den Berg, E.A., Sprengers, E.D., Jaye, M., Burgess, W., Maciag, T. and van Hinsbergh, V.W.M. 1988. Regulation of Plasminogen Activator Inhibitor-1 mRNA in Human Endothelial Cells. Thromb. Haemost. 60: 63-67.